Chemoenzymatic synthesis of building blocks for statin side chains

Angewandte Chemie - International Edition

Volumn 44, Issue 3, 2005, Pages 362-365

  Müller, Michael ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Enzyme catalysis; Inhibitors; Natural products; Statins steroids

Indexed keywords

BIOSYNTHESIS; CATALYSIS; CHOLESTEROL; DRUG PRODUCTS; MOLECULAR DYNAMICS; ORGANIC COMPOUNDS;

BIOCATALYSIS; CHEMOENZYMATIC SYNTHESIS; ENZYMATIC TRANSFORMATIONS; STATINS;

ENZYME KINETICS;

ATORVASTATIN; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; ORGANIC COMPOUND; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN;

BIOCATALYST; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SYNTHESIS; HUMAN; REVIEW;

ALCOHOL DEHYDROGENASE; GLUCOSE 1-DEHYDROGENASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 12344273661     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200460852     Document Type: Review

References (39)

1. According to the Anatomical Therapeutic Chemical (ATC) classification of the World Health Organization, the International Nonproprietary Names (INN) of the so-called "statins" are assigned the root "-vastatin".
2. Coronary heart disease is a leading cause of death and morbidity in the developed world; a) J. A. Tobert, Nat. Rev. Drug Discovery 2003, 2, 517-526; b) H. Stark. Pharm. Unserer Zeit 2003, 32, 464-470; c) D. Manns, Pharm. Unserer Zeit 1999, 28, 147-152.
3. Coronary heart disease is a leading cause of death and morbidity in the developed world; a) J. A. Tobert, Nat. Rev. Drug Discovery 2003, 2, 517-526; b) H. Stark. Pharm. Unserer Zeit 2003, 32, 464-470; c) D. Manns, Pharm. Unserer Zeit 1999, 28, 147-152.
4. Coronary heart disease is a leading cause of death and morbidity in the developed world; a) J. A. Tobert, Nat. Rev. Drug Discovery 2003, 2, 517-526; b) H. Stark. Pharm. Unserer Zeit 2003, 32, 464-470; c) D. Manns, Pharm. Unserer Zeit 1999, 28, 147-152.
5. B. D. Roth, Prog. Med. Chem. 2002, 42, 1-22.
6. a) J. Quirk, M. Thornton, P. Kirkpatrick, Nat. Rev. Drug Discovery 2003, 2, 769-770;
7. b) C. I. Carswell, G. L. Plosker, B. Jarvis, Drugs 2002, 62, 2075-2085;
8. c) M. Watanabe, H. Koike, T. Ishiba, T. Okada, S. Seo, K. Hirai, Bioorg. Med. Chem. 1997, 5, 437-444.
9. Cerivastatin, marketed by Bayer, was withdrawn from the market in 2001 because of reported cases of rhabdomolysis (severe muscular toxicity).
10. Fluvastatin is marketed as a racemate.
11. a) Y. Yasohara, N. Kizaki, J. Hasegawa, M. Wada, M. Kataoka, S. Shimizu, Tetrahedron: Asymmetry 2001, 12, 1713-1718;
12. b) N. Kizaki, Y. Yasohara, J. Hasegawa, M. Wada, M. Kataoka, S. Shimizu, Appl. Microbiol Biotechnol. 2001, 55, 590-595;
13. c) M. Kataoka, L. P. S. Rohani, K. Yamamoto, M. Wada, H. Kawabata, K. Kita, H. Yanase, S. Shimizu, Appl. Microbiol. Biotechnol. 1997, 48, 699-703.
14. a) M. Ernst, B. Kaup, M. Müller, S. Bringer-Meyer, H. Sahm, Appl. Microbiol. Biotechnol. 2005, DOI: 10.1007/s00253-004-1765-5;
15. b) T. Endo, S. Kiozumi, Adv. Synth. Catal. 2001, 343, 521-526.
16. a) A. J. Blacker, R. A. Holt, C. D. Reeve (Avecia Pharmaceuticals), WO 01/85 975, 2001;
17. b) C. D. Reeve (Avecia Pharmaceuticals), WO 97/00 968, 1997.
18. N. Kizaki, Y. Yamada, Y. Yasohara, A. Nishiyama, M. Miyazaki, M. Mitsuda, T. Kondo, N. Ueyama, K. Inoue (Kaneka), WO 00/08 011, 2000.
19. a) R. N. Patel, A. Banerjee, C. G. McNamee, D. Brzozowski, R. L. Hanson, L. J. Szarka, Enzyme Microb. Technol. 1993, 15, 1014-1021;
20. b) R. N. Patel, C. G. McNamee, A. Banerjee, L. J. Szarka (Squibb & Sons, Inc.), Eur. Pat. Appl. EP 569,998, 1993 [Chem. Abstr. 1994, 120, 52 826q].
21. F.-C. Huang, L. F. H. Lee, R. S. D. Mittal, P. R. Ravikumar, J. A. Amigo, C. J. Sih, E. Caspi, C. R. Eck, J. Am. Chem. Soc. 1974, 96, 4144-4145.
22. R. Öhrlein, G. Baisch, Adv. Synth. Catal. 2003, 345, 713-715.
23. See also: S. J. C. Taylor, R. C. Brown, P. A. Keene, I. N. Taylor, Bioorg. Med. Chem. 1999, 7, 2163-2168.
24. a) G. DeSantis, K. Wong, B. Farwell, K. Chatman, Z. Zhu, G. Tomlinson, H. Huang, X. Tan, L. Bibbs, P. Chen, K. Kretz, M. J. Burk, J. Am. Chem. Soc. 2003, 125, 11 476-11 477;
25. b) G. DeSantis, Z. Zhu, W. A. Greenberg, K. Wong, J. Chaplin, S. R. Hanson, B. Farwell, L. W. Nicholson, C. L. Rand, D. P. Weiner, D. E. Robertson, J. Burk, J. Am. Chem. Soc. 2002, 124, 9024-9025;
26. c) see also: S. J. Maddrell, N. J. Turner, A. Kerridge, A. J. Willetts, J. Crosby, Tetrahedron Lett. 1996, 37, 6001-6004.
27. a) N. Kasai, T. Suzuki, Adv. Synth. Catal. 2003, 345, 437-455;
28. b) T. Suzuki, H. Idogaki, N. Kasai, Enzyme Microb. Technol. 1998, 24, 13-20.
29. T. Nakamura, T. Nagasawa, F. Yu, I. Watanabe, H. Yamada, Tetrahedron 1994, 50, 11 821-11 826.
30. E. J. de Vries, D. B. Janssen, Curr. Opin. Biotechnol. 2003, 14, 414-420.
31. S. C. Davis, J. H. Grate, D. R. Gray, J. M. Gruber, G. W. Huisman, S. K. Ma, L. M. Newman, R. Sheldon, L. A. Wang (Codexis Inc.), WO 2004/015 132.
32. a) J. G. T. Kierkels, D. Mink, S. Panke, F. A. M. Lommen, D. Heemskerk (DSM), WO 03/006 656;
33. b) J. M. H. H. Kooistra, H. J. M. Zeegers, D. Mink, J. M. C. A. Mulders (DSM), WO 02/06 266;
34. c) M. Wubbolts, Screening and biocatalyst development for custom manufacturing of fine chemicals, Biocat, Barcelona, Spain, 2003.
35. a) H. J. M. Gijsen, C.-H. Wong, J. Am. Chem. Soc. 1994, 116, 8422-8423;
36. b) C.-H. Wong, E. Garcia-Junceda, L. Chen, O. Blanco, H. J. M. Gijsen, D. H. Steensma, J. Am. Chem. Soc. 1995, 117, 3333-3339;
37. c) G. DeSantis, J. Liu, D. P. Clark, A. Heine, I. A. Wilson, C.-H. Wong, Bioorg. Med. Chem. 2003, 11, 43-52;
38. d) J. Liu, C.-C. Hsu, C.-H. Wong, Tetrahedron Lett. 2004, 45, 2439-2441.
39. W. A. Greenberg, A. Varvak, S. R. Hanson, K. Wong, H. Huang, P. Chen, M. J. Burk, Proc. Natl. Acad. Sci. USA 2004, 101, 5788-5793.